Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) saw unusually-high trading volume on Tuesday . Approximately 719,539 shares were traded during trading, an increase of 32% from the previous session’s volume of 543,220 shares.The stock last traded at $14.14 and had previously closed at $14.35.

Silence Therapeutics News Summary

Here are the key news stories impacting Silence Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $1.14 from $1.38 and its FY2027 estimate to a loss of $1.38 from $1.74. The firm also improved estimates for the third and fourth quarters of 2026 and all four quarters of 2027, indicating expectations for better-than-previously forecast financial performance. MarketBeat analyst estimate report
• Positive Sentiment: Longer-term estimates were generally revised favorably: FY2028 losses were reduced to $1.53 per share from $1.65, and FY2030 losses to $1.50 from $1.77. The $75 target implies substantial upside if Silence’s pipeline and commercialization plans develop as expected. MarketBeat analyst estimate report
• Neutral Sentiment: A recent Seeking Alpha article, “Silence Therapeutics: Making Some Recent Noise,” highlights renewed investor attention around the company. However, the provided article details do not identify a specific new clinical, regulatory, or commercial catalyst. Silence Therapeutics: Making Some Recent Noise
• Negative Sentiment: HC Wainwright lowered its FY2029 EPS estimate to a loss of $1.92 from $1.74, showing that the path to profitability remains uncertain. The company is still expected to post substantial losses, which may help explain near-term volatility despite the optimistic analyst target.

Analyst Upgrades and Downgrades

SLN has been the subject of a number of recent research reports. Cantor Fitzgerald began coverage on shares of Silence Therapeutics in a report on Wednesday, June 24th. They issued an “overweight” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Finally, Morgan Stanley raised their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.50.

Silence Therapeutics Price Performance

The company’s 50-day moving average is $10.57 and its two-hundred day moving average is $7.68. The firm has a market cap of $643.07 million, a P/E ratio of -10.63 and a beta of 1.39.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. On average, analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SLN. Nantahala Capital Management LLC lifted its stake in Silence Therapeutics by 48.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after purchasing an additional 500,000 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Silence Therapeutics by 121.0% during the 4th quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after buying an additional 361,080 shares in the last quarter. 5AM Venture Management LLC bought a new stake in shares of Silence Therapeutics during the 2nd quarter worth $5,228,676,000. UBS Group AG lifted its position in shares of Silence Therapeutics by 34.5% during the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock worth $1,595,000 after buying an additional 78,854 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in Silence Therapeutics by 11.8% in the first quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock valued at $1,511,000 after buying an additional 30,358 shares in the last quarter. 98.73% of the stock is owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.